Neil Lattin, MD
Family Medicine · Rising Sun, MDNPI 1508818162
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 47 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 24.6% of the total. 2024 is the largest year on record at $534, 2.1 times the $258 reported in 2019.
Across 47 payments — averaging $21.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$246
- Lilly USA, LLC$86
- Johnson & Johnson$80
- Novartis$67
- Pfizer$63
- AstraZeneca$56
- plus $401 from 16 others
What the payments were for
- Food & beverage$1,000100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 10 | $246 |
| Lilly USA, LLC | 5 | $86 |
| Johnson & Johnson | 3 | $80 |
| Novartis | 4 | $67 |
| Pfizer | 3 | $63 |
| AstraZeneca | 3 | $56 |
| Exact Sciences | 2 | $53 |
| GSK | 2 | $48 |
| Tactile Systems Technology Inc | 1 | $37 |
| Merck | 2 | $31 |
| Astellas Pharma US Inc | 1 | $30 |
| Amgen | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Bristol Myers Squibb | 1 | $24 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Novo Nordisk | 1 | $15 |
| Medtronic | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
| Alkermes, Inc. | 1 | $13 |
How this compares
$1,000 in reported general payments places this provider in the 65th percentile of 1,193 family medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 78 | $79,262 |
| EliquisApixaban | 108 | $58,680 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $33,916 |
| TrulicityDulaglutide | 25 | $27,409 |
| XareltoRivaroxaban | 39 | $27,172 |
| JanuviaSitagliptin Phosphate | 16 | $22,772 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $14,059 |
| Incruse ElliptaUmeclidinium Bromide | 30 | $13,607 |
| Emgality PenGalcanezumab-Gnlm | 14 | $12,698 |
| LinzessLinaclotide | 19 | $11,715 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 41 | $11,471 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $8,955 |
| Sumatriptan Succinate | 26 | $8,501 |
| EntrestoSacubitril/Valsartan | 12 | $7,429 |
| TrulancePlecanatide | 12 | $7,300 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $15 | $79,26278 claims |
| PfizerEliquis, Paxlovid | $63 | $61,477128 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta | $48 | $56,47887 claims |
| Lilly USA, LLCTrulicity | $86 | $27,40925 claims |
| Johnson & JohnsonXarelto | $80 | $27,17239 claims |
| MerckJanuvia | $31 | $22,77216 claims |
| AbbVieLinzess | $246 | $11,71519 claims |
| NovartisEntresto | $67 | $7,42912 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $15 | $7,30012 claims |
| AstraZenecaSymbicort | $56 | $6,91016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,193 family medicine providers in Maryland.
Other family medicine in Rising Sun
- Karen DonaldsonBaltimore$899K
- Louis JacquesBaltimore$522K
- Michael ObiefuneBaltimore$291K
- Thomas LawrenceBerlin$254K
- Casey ScottCambridge$88K
- Daljeet SalujaBaltimore$63K
- Sanjay SaxenaHagerstown$60K
- Cynthia KleppingerSilver Spring$51K
- Tramaine DavisBowie$43K
- Alkesh PatelColumbia$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.